|
UW17114
|
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
|
Open |
|
UW16061
|
A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) |
Open |
|
UW17086
|
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ubilituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
|
Open |
|
NCI9924
|
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) |
Open |
|
PRE0404
|
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma |
Open |
|
UW17064
|
A Phase II, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
|
Open |
|
UW18069
|
A Randomized Phase 3 Study to Evaluate the Efficcy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGMI
|
Open |
|
EA4151
|
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Cell Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission |
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW16144
|
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
|
Open |
|
UW16086
|
Bendamustine + obinutuzumab induction chemoimmunotherapy with risk-adapted obinutuzumab maintenance therapy in previously untreated mantle cell lymphoma |
Open |
|
UW17038
|
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) |
Open |
|
OS11366
|
FAS Apoptotic Pathway Abnormalities in Cutaneous T-Cell Lymphomas
|
Open (affiliates only) |
|
UW15106
|
Genomic Analysis of Long-Term Survivors with Metastatic Cancer |
Open |
|
UW17096
|
Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach
|
Open |
|
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621H
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. |
Open |
|
APEC1621C
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tazemetostat in Patients with tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex |
Not Open |
|
APEC1621E
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621J
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
APEC1621I
|
NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes |
Open |
|
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
|
HO11414
|
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab + Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
Open |
|
PRE0403
|
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patient with High Tumor Burden Follicular Lymphoma
|
Open |
|
UW17147
|
Pre-Visit Planning in Palliative Care |
Open |
|
APEC14B1
|
Project: Every Child A Registry, Eligibility Screening, Biology and Outcome Study |
Open |
|
S1608
|
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma |
Open |
|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
UW Carbone